EUVIMEDEUVIMED entdecken
Open Access

Improving Access to Patient-Focused, Decentralized Clinical Trials Requires Streamlined Regulatory Requirements: An ASCO Research Statement

Ramya Thota iD, Patricia A Hurley iD, Therica M Miller iD, Suanna S Bruinooge iD, Craig Lipset, R Donald Harvey iD, Lora J Black iD, Amanda Dinsdale iD, Janette K Merrill iD, Teri Pollastro, Sheila A Prindiville, Mujahid A Rizvi und 2 weitere

Journal of Clinical Oncology · 20.11.2024 · 42 (33) · 3986-3995

DOI: 10.1200/jco.24.00961 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.11.2024. Verfasst von Ramya Thota und 13 weiteren Autor:innen. Beteiligte Einrichtung: Intermountain Health, Murray, UT. Hauptthemen laut MEDLINE: Clinical Trials as Topic, COVID-19. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Strategies to bring clinical trials closer to patients gained momentum during the COVID-19 pandemic, enabling more participants to receive treatment and/or testing in their local communities. Incorporation of decentralized trial elements presents both opportunities and challenges, spanning regulatory, technical, and operational aspects. This ASCO research statement includes timely consensus-driven recommendations and a call for engagement of all research stakeholders. ASCO held multistakeholder meetings with leaders in oncology research and concluded that research-related regulatory and administrative requirements and burdens present critical barriers to decentralizing trials. One example is sponsor and contract research organization (CRO) use of US Food and Drug Administration (FDA)'s Statement of Investigator (Form 1572), which was found to exceed FDA's stated intent and used in conservative ways disproportionate to potential risks to participants and scientific integrity. As a result, research sites experience an avalanche of downstream administrative and regulatory activities that consume considerable resources. This statement recommends four key solutions to address such barriers and recalibrate regulatory and administrative expectations for decentralizing trials: (1) FDA should engage the research community in a public-private partnership to modernize standards and enable local access to trials; (2) sponsors and CROs should develop standards and protocols that accommodate flexible approaches, enable local participation, provide clarity around roles and requirements, and promote consistency; (3) research centers, networks, and sites should update policies and procedures to implement decentralized trial elements; and (4) research community should develop a streamlined, uniform mechanism to simplify regulatory data collection and documentation and use it consistently across trials. We can and must prioritize a concerted commitment to simplify and streamline regulatory requirements and practices to broaden access to and participation in cancer clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicCOVID-19HumansUnited StatesMedical OncologyHealth Services AccessibilityUnited States Food and Drug AdministrationNeoplasmsSARS-CoV-2Patient-Centered Care

Autor:innen und Institutionen

  • Intermountain Health, Murray, UT.
  • American Society of Clinical Oncology, Alexandria VA.
  • Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY.
  • Decentralized Trials and Research Alliance, San Diego, CA.
  • Winship Cancer Institute of Emory University, Atlanta, GA.
  • Sanford Health, Sioux Falls, SD.

ORCID-Profile: Ramya Thota, Patricia A Hurley, Therica M Miller, Suanna S Bruinooge, R Donald Harvey, Lora J Black, Amanda Dinsdale, Janette K Merrill, Grzegorz S Nowakowski

Förderung

  • Intramural NIH HHS

Zitieren

APA

Thota, R., Hurley, P. A., Miller, T. M., Bruinooge, S. S., Lipset, C., Harvey, R. D., Black, L. J., Dinsdale, A., Merrill, J. K., Pollastro, T., Prindiville, S. A., Rizvi, M. A., Sherwood, S., & Nowakowski, G. S. (2024). Improving Access to Patient-Focused, Decentralized Clinical Trials Requires Streamlined Regulatory Requirements: An ASCO Research Statement. Journal of Clinical Oncology, 42(33), 3986-3995. https://doi.org/10.1200/jco.24.00961

Vancouver

Thota R, Hurley PA, Miller TM, Bruinooge SS, Lipset C, Harvey RD, et al. Improving Access to Patient-Focused, Decentralized Clinical Trials Requires Streamlined Regulatory Requirements: An ASCO Research Statement. Journal of Clinical Oncology. 2024;42(33):3986-3995. doi:10.1200/jco.24.00961

BibTeX
@article{Thota2024,
  author = {Thota, Ramya and Hurley, Patricia A and Miller, Therica M and Bruinooge, Suanna S and Lipset, Craig and Harvey, R Donald and Black, Lora J and Dinsdale, Amanda and Merrill, Janette K and Pollastro, Teri and Prindiville, Sheila A and Rizvi, Mujahid A and Sherwood, Shimere and Nowakowski, Grzegorz S},
  title = {Improving Access to Patient-Focused, Decentralized Clinical Trials Requires Streamlined Regulatory Requirements: An ASCO Research Statement},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {33},
  pages = {3986--3995},
  doi = {10.1200/jco.24.00961}
}
Kostenlos starten →